Expanded Access Protocol for Niraparib in Patients With Recurrent Ovarian Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03025867|
Recruitment Status : Approved for marketing
First Posted : January 20, 2017
Last Update Posted : April 17, 2017
This is an expanded access program (EAP) for eligible patients with Recurrent Ovarian Cancer.
This program is designed to provide access to niraparib prior to approval by the US Food and Drug Administration (FDA).
To be eligible, patients with Recurrent Ovarian Cancer following a partial (PR) or complete response (CR) to their most recent platinum-based chemotherapy and must have experienced a PR or CR after the penultimate (next to last) platinum-based chemotherapy for at least 6 months without disease progression after this chemotherapy.
|Condition or disease||Intervention/treatment|
|Recurrent Ovarian Cancer||Drug: Niraparib|
If a patient qualifies for participation in an ongoing niraparib clinical trial or is already participating in a niraparib clinical trial, she will not be able to participate in the EAP.
Ongoing clinical trials for niraparib include:
- A Phase 3 trial in patients who have received first-line treatment for ovarian cancer (the PRIMA trial, NCT # 02655016)
- A Phase 2 trial in patients who have received multiple lines of treatment for ovarian cancer (the QUADRA trial, NCT # 02354586)
- A Phase 1/2 trial in patients with advanced or metastatic triple-negative breast cancer or recurrent ovarian cancer. (the TOPACIO trial, NCT # 02657889)
|Study Type :||Expanded Access|
|Official Title:||Expanded Access Protocol for Niraparib in Patients With Recurrent Ovarian Cancer|
U.S. FDA Resources